The introduction of small molecule TKIs has contributed to marked improvements in the therapeutic outcomes of CML by forcefully blocking phosphorylation by the BCR-ABL1 oncoprotein and inhibiting its cell signal transduction activity [10–12]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.